Tags

Type your tag names separated by a space and hit enter

The effect of aerosolized SK&F 104353-Z2 on the bronchoconstrictor effect of leukotriene D4 in asthmatics.
Pulm Pharmacol. 1991; 4(1):37-42.PP

Abstract

Leukotriene D4 (LTD4) is a potent bronchoconstrictor and vasoactive mediator that has been implicated in the pathogenesis of bronchial asthma. We have studied the effect of SK&F 104353-Z2, a specific LTD4 antagonist, on LTD4-induced bronchoconstriction in asthmatics. A total of 12 mild asthmatics (mean baseline FEV1 +/- SEM: 85.9% +/- 2.6) received on 2 separate days, double-blind and cross-over, 800 micrograms SK&F 104353-Z2 or placebo via aerosol. After 30 min, doubling concentrations of LTD4 (0.078 to 20.1 microM in the first 4 patients and up 80.4 microM in the other patients) were inhaled with intervals of 30 min. Specific airways conductance (sGaw) and forced expiratory volume in 1 s (FEV1) were measured. On the placebo-day LTD4 inhalation caused a concentration dependent bronchoconstriction. The effect of SK&F 104353-Z2 on baseline sGaw and FEV1 could be evaluated in 10 patients. After inhalation of SK&F 104353-Z2 a small, but significant increase, in sGaw (0.107 +/- 0.013 to 0.132 +/- 0.011 cm H2O-1s-1) and FEV1 (3.39 +/- 0.23 to 3.56 +/- 0.25 liter) was observed. The effect of SK&F 104353-Z2 on the dose-response curve for LTD4 was evaluated in the six patients who inhaled concentrations of LTD4 up to 80 microM. On the active treatment day, the dose-response curve for LTD4 was significantly shifted to the right.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Department of Respiratory Diseases, University Hospital, Ghent, Belgium.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

1804493

Citation

Joos, G F., et al. "The Effect of Aerosolized SK&F 104353-Z2 On the Bronchoconstrictor Effect of Leukotriene D4 in Asthmatics." Pulmonary Pharmacology, vol. 4, no. 1, 1991, pp. 37-42.
Joos GF, Kips JC, Pauwels RA, et al. The effect of aerosolized SK&F 104353-Z2 on the bronchoconstrictor effect of leukotriene D4 in asthmatics. Pulm Pharmacol. 1991;4(1):37-42.
Joos, G. F., Kips, J. C., Pauwels, R. A., & Van der Straeten, M. E. (1991). The effect of aerosolized SK&F 104353-Z2 on the bronchoconstrictor effect of leukotriene D4 in asthmatics. Pulmonary Pharmacology, 4(1), 37-42.
Joos GF, et al. The Effect of Aerosolized SK&F 104353-Z2 On the Bronchoconstrictor Effect of Leukotriene D4 in Asthmatics. Pulm Pharmacol. 1991;4(1):37-42. PubMed PMID: 1804493.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of aerosolized SK&F 104353-Z2 on the bronchoconstrictor effect of leukotriene D4 in asthmatics. AU - Joos,G F, AU - Kips,J C, AU - Pauwels,R A, AU - Van der Straeten,M E, PY - 1991/1/1/pubmed PY - 1991/1/1/medline PY - 1991/1/1/entrez SP - 37 EP - 42 JF - Pulmonary pharmacology JO - Pulm Pharmacol VL - 4 IS - 1 N2 - Leukotriene D4 (LTD4) is a potent bronchoconstrictor and vasoactive mediator that has been implicated in the pathogenesis of bronchial asthma. We have studied the effect of SK&F 104353-Z2, a specific LTD4 antagonist, on LTD4-induced bronchoconstriction in asthmatics. A total of 12 mild asthmatics (mean baseline FEV1 +/- SEM: 85.9% +/- 2.6) received on 2 separate days, double-blind and cross-over, 800 micrograms SK&F 104353-Z2 or placebo via aerosol. After 30 min, doubling concentrations of LTD4 (0.078 to 20.1 microM in the first 4 patients and up 80.4 microM in the other patients) were inhaled with intervals of 30 min. Specific airways conductance (sGaw) and forced expiratory volume in 1 s (FEV1) were measured. On the placebo-day LTD4 inhalation caused a concentration dependent bronchoconstriction. The effect of SK&F 104353-Z2 on baseline sGaw and FEV1 could be evaluated in 10 patients. After inhalation of SK&F 104353-Z2 a small, but significant increase, in sGaw (0.107 +/- 0.013 to 0.132 +/- 0.011 cm H2O-1s-1) and FEV1 (3.39 +/- 0.23 to 3.56 +/- 0.25 liter) was observed. The effect of SK&F 104353-Z2 on the dose-response curve for LTD4 was evaluated in the six patients who inhaled concentrations of LTD4 up to 80 microM. On the active treatment day, the dose-response curve for LTD4 was significantly shifted to the right.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0952-0600 UR - https://www.unboundmedicine.com/medline/citation/1804493/The_effect_of_aerosolized_SK&F_104353_Z2_on_the_bronchoconstrictor_effect_of_leukotriene_D4_in_asthmatics_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0952-0600(91)90037-4 DB - PRIME DP - Unbound Medicine ER -